Navigation Links
ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer

PHILADELPHIA, Sept. 10 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERES), a global provider of technology and services to the pharmaceutical, biotechnology, and medical device industries, today announced that Michael McKelvey will be retiring from his positions as President and Chief Executive Officer and a director of ERT.  The Company's Board of Directors has begun a search for a successor.  Dr. McKelvey will continue in his current position until a successor is appointed or earlier, based on mutual agreement of Dr. McKelvey and the Board.

"I am honored to have led ERT for more than four years," commented Dr. McKelvey. "The acquisition of CareFusion Research Services and the emerging opportunities in healthcare represent a fundamental strategic shift in our business. The Company has transformed into a multi-product and service provider.  We have built a strong, well-diversified company that is very well positioned for growth in the future.  After over four years at the helm and at the age of 58, I feel the time is right to retire from this marvelous Company, focus on other interests, and devote more time to my family.  I leave ERT in a strong financial position, with a well diversified portfolio of products and services focused in cardiac safety, respiratory, multi-mode ePRO, and medical devices that can serve the research, pharmaceutical safety, and healthcare markets, a well thought out strategic vision and focus, and an excellent group of senior executives who individually and as a group are outstanding. We have achieved this due largely to the support of our employees, customers, the Board, and investors, and I would like to take this opportunity to thank them."  

Commenting on behalf of the Board of Directors, ERT's Chairman, Joel Morganroth, MD, said, "The Board accepts Mike's decision to retire with understanding and gratitude.  Mike leaves our Company positioned for future growth in the clinical research, pharmaceutical marketing, and healthcare markets.  The Board appreciates Mike's commitment to a successful transition while it conducts its search for a successor and wishes him the very best. The Company has retained Heidrick and Struggles, one of the nation's leading executive search firms, to assist in its search and will consider both internal and external candidates."

About eResearchTechnology, Inc.

Based in Philadelphia, PA, eResearchTechnology, Inc. ( is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development.  It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  ERT also provides solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as providing selected medical devices for the clinical trials and healthcare industries.  

This release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events.  These statements can be identified by the fact that they do not relate strictly to historical or current facts.  They use words such as "will," "will continue" and other words and terms of similar meaning in conjunction with a discussion of future events.  These statements are subject to risks and uncertainties that could cause actual events to differ materially from those expressed or implied in the forward-looking statements. Factors that might cause such a difference include unanticipated delays in recruiting a suitable successor for Dr. McKelvey or changes in Dr. McKelvey's ability or willingness to continue to serve during this transition process.

Forward-looking statements speak only as of the date made.  We undertake no obligation to update any forward-looking statements, including prior forward-looking statements, to reflect the events or circumstances arising after the date as of which they were made.  As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included in this release or that may be made in our filings with the Securities and Exchange Commission or elsewhere from time to time by, or on behalf of, us.

SOURCE eResearchTechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sysmex America Announces LabCorp Hematology Automation Agreement
2. K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market
3. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
4. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
5. Misonix Announces New Distribution Agreement For Spain
6. Dehaier Medical Systems Announces Engagement of RedChip Companies to Lead Public and Investor Relations
7. Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
8. ResMed Inc. Announces Completion of Two-for-One Stock Split
9. Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period
10. Halozyme Therapeutics Announces Public Offering of Common Stock
11. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
Post Your Comments:
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 ... overview on therapeutic pipeline of Endometriosis and ... effective counter strategies to gain competitive advantage. ... targets and MOAs to produce first-in-class and ...
(Date:11/30/2015)... CUPERTINO, Calif. , Nov. 30, 2015 ... announced today that Matt Hogan , ... the Oppenheimer Healthcare Conference on Tuesday, December ... conference is being held at the Westin ... will also be available for one-on-one meetings ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... RoamRight, a ... up with Public Television’s Travel With Kids to promote family vacations ... Simmons family as they explore international destinations and educate families about the people and ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of ... be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant ... that small molecule analogs that target the functions of SecA, a central part ...
(Date:11/30/2015)... Plains, NJ (PRWEB) , ... November 30, 2015 , ... ... in a comfortable and convenient setting. , When you have dental problems, you need ... the field and can effectively diagnose and treat your needs, a friendly dentist who ...
(Date:11/30/2015)... ... ... Using a combination of two blood sugar tests rather than a single test ... study by researchers at the School of Public Health at Georgia State University. , ... Glucose Tests ,” published in Frontiers in Public Health, the researchers noted that 24 ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... general dentistry out of Glen Ridge, NJ. He has both advanced training ... optimal mastication. He is also an expert in cosmetic dentistry. He is ...
Breaking Medicine News(10 mins):